PowerShares Dynamic Biotechnology & Genome Portfolio ETF(PBE)- NYSEARCA
  • Oct. 13, 2015, 3:49 PM
    • Getting out in front of what should be more bashing of their business models at the Democratic debate tonight, the healthcare names (XLV -1.3%) have about doubled the decline in the S&P 500. Within healthcare, it's the biotechs (IBB -3.1%) and pharmaceuticals (XPH -3.2%) leading the way south.
    • Celgene (CELG -3.3%), Biogen (BIIB -3.6%), Amgen (AMGN -3.5%), Allergan (AGN -4.1%), Mylan (MYL -3.6%)
    • The biotech heavy Russell 2000 (IWM -1.4%) is feeling the pain as well.
    • ETFs: IBB, IYH, XLV, XBI, VHT, PJP, BBH, FBT, HQH, CURE, XPH, HQL, PBE, FXH, RXL, IHE, FHLC, SBIO, PPH, RYH, BBC, THQ, BBP, RXD, LABU, LABD, UBIO, ZBIO
    | Oct. 13, 2015, 3:49 PM | 27 Comments
  • Sep. 25, 2015, 3:07 PM
    | Sep. 25, 2015, 3:07 PM | 134 Comments
  • Sep. 21, 2015, 12:56 PM
    • The iShares Nasdaq Biotechnology Index Fund (IBB -5%) is down on increased volume, as well as many other ETFs and individual stocks, in apparent response by a tweet by presidential candidate Hillary Clinton stating that price gouging in the specialty drug market is outrageous. Tomorrow, she will "lay out a plan" to take it on.
    • ETFs: IBB, XBI, BBH, FBT, HQL, PBE, SBIO, BBC, BBP, LABD, UBIO, LABU, ZBIO
    | Sep. 21, 2015, 12:56 PM | 83 Comments
  • Jun. 9, 2014, 2:53 PM
    • Those ETFs with more small- and mid-cap exposure like the SPDR S&P Biotech ETF (XBI +5.7%) and the PowerShares Dynamic Biotechnology & Genome Portfolio (PBE +7.4%) are partying. It also turns out the XBI and PBE are the two largest holders of Idenix stock.
    • Biotech ETFs with a focus on large caps - the iShares Nasdaq Biotechnology ETF (IBB +0.5%) and the Market Vectors Biotech ETF (BBH +0.4%) - are having more subdued sessions.
    • Previously: Merck buys Idenix
    • The rally in small cap biotech fueling a positive session for small caps overall, with the Russell 2000's (IWM +0.7%) gain outpacing the flat action in the big-cap averages.
    | Jun. 9, 2014, 2:53 PM
  • Apr. 25, 2014, 1:31 PM
    • Today's selloff is following the pattern of most in the past few weeks, with the small caps (IWM -1.9%) and tech (QQQ -1.5%) leading the way. Pacing declines in the Nasdaq are a 8.8% dive in Amazon post-earnings and a 4.6% fall in Facebook. Setting tongues wagging in FB - but hardly a huge deal - is the sale of another 283K shares by Sheryl Sandberg, bringing her holdings down to 8.7M shares.
    • The liquidation in biotech has previously been a convenient excuse for small cap selloffs, but the IBB is off just 1.4% today, outperforming the Russell 2000.
    • What's working? Utilities again. The XLU +0.8% today and +13% this year, outperforming the Russell 2000 by about 1.6K basis points.
    • Small cap ETFs: IWM, TZA, TNA, UWM, VB, IJR, SLY, RWJ, URTY, SCHA, TWM, RWM, SRTY, SAA, DWAS, VTWO, SDD, VIOO, JKJ, RSCO, SBB, FYX, XSLV, EWRS, TWOK, SMLV, PXSC
    • Utility ETFs: XLU, IDU, VPU, NLR, GRID, JXI, NUCL, DBU, IPU, UPW, RYU, PUI, FUTY, FXU, SDP, PSCU, UTLT
    • Biotech ETFs: IBB, XBI, BIB, BBH, FBT, PBE, BIS
    | Apr. 25, 2014, 1:31 PM | 7 Comments
  • Apr. 10, 2014, 11:09 AM
    | Apr. 10, 2014, 11:09 AM | 6 Comments
  • Jan. 28, 2014, 9:12 AM
    • Deutsche's Robyn Karnauskas makes a big call on big-cap biotechs, boosting price targets for Biogen (BIIB) to $415 from $340, Celgene (CELG) to $190 from $170, and Gilead (GILD) to $132 from $95. The $132 PT for Gilead is a new Street high "by a nautical mile," says Notable Calls, and Karnauskas sees upside all the way to $165.
    • "We view large-cap biotech as fundamentally stable yet providing attractive growth," she writes, citing more diversified businesses, pipelines, new product launches, strong balance sheets, and strong free cash flow. "Therefore, we are changing our valuation methodology to 2015 PE multiples from DCF for Gilead, Celgene, and Biogen. Our '15 EPS estimates are higher than consensus and we think near-term franchise success could drive re-rating."
    • GILD +2.7%, CELG +1.3% premarket
    • Related ETFs: IBB, XBI, BIB, BBH, FBT, PBE, BIS
    | Jan. 28, 2014, 9:12 AM | 1 Comment
  • Jan. 27, 2014, 10:52 AM
    • A little bit more air comes out of the previously scorching small-cap biotech names today. Among them: CytRx (CYTR -4.8%), Dyax (DYAX -5.2%), Galena (GALE -9.6%), Novavax (NVAX -9%), Arena (ARNA -6.3%), Synta (SNTA -10.8%), Zogenix (ZGNX -3.5%), Tonix (TNXP -8.4%).
    • Biotech ETFs: IBB, XBI, BIB, BBH, FBT, PBE, BIS
    | Jan. 27, 2014, 10:52 AM | 23 Comments
  • Oct. 10, 2013, 11:57 AM
    • Biotechs took a beating in the first three days of this week but they're rallying today, so investors need to decide whether they should be using the dip to buy or the bounce to sell.
    • Citi sees a mixed view for the sector: Given the scarcity of growth stocks in the overall market, the firm expects large-cap biotechs to bounce back but is far less sanguine about small- and mid-caps where valuations are broadly stretched and the Street is overly optimistic of the chances for pipeline success.
    • The firm's favorites include Gilead (GILD +4.7%) and Celgene (CELG +3.5%), and sees compelling risk/reward in Medivation (MDVN +3.9%) and Tesaro (TSRO +5.7%).
    • ETFs: IBB, XBI, FBT, PBE, BBH, BIB, BIS.
    | Oct. 10, 2013, 11:57 AM
  • Sep. 26, 2013, 10:43 AM
    • Cramer says biotech is a safe haven amid the uncertainty emanating from Washington, as pipelines are strong and the sector is not sensitive to the trajectory of the overall economy — this is a "double advantage", he says.
    • Celldex (CLDX +5.3%) — which is part of this week's billion dollar biotech price target bump club courtesy of Leerink and Cantor  — gets a glowing recommendation as Cramer calls the company "just incredible."
    • Other companies getting a name drop: Celgene (CELG +2.4%), Immunogen (IMGN +2%), and Onyx (ONXX).
    • ETFs - IBB, XBI, FBT, PBE, BBH, BIB, BIS
    | Sep. 26, 2013, 10:43 AM
  • Mar. 12, 2012, 12:07 PM
    Shares of Anthera Pharmaceuticals (ANTH -52.1%) can't stop the freefall that was triggered by Friday's announcement that it's canceling its late-stage trial of its experimental treatment for heart disease. Adam Feuerstein eyes the recent carnage with a number of biotech names to conclude that "fail" is now re-entering the lexicon of investors in the sector.
    | Mar. 12, 2012, 12:07 PM
  • Aug. 4, 2011, 4:05 PM

    Dendreon (DNDN -67.4%) takes down an entire industry, with the Amex Biotech index falling an astonishing 10.4%. "Biotech risk takers burned on this one might be less risk tolerant going forward," one analyst explains. "The biotech group does work like that, especially for product failures." IBB -7.9%. XBI -9.8%.

    | Aug. 4, 2011, 4:05 PM
  • Apr. 29, 2011, 11:53 AM
    A 2-1 ruling by a federal appeals court overturns a ban on federal stem-cell funding. STEM +8.1%, ASTM +2.6%, GERN +1%, CYTX +0.4%; PowerShares biotech and genome ETF (PBE) +0.3%.
    | Apr. 29, 2011, 11:53 AM | 6 Comments
PBE Description
The PowerShares Dynamic Biotechnology & Genome Portfolio (Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (Index). The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.
See more details on sponsor's website
Sector: Healthcare
Country: United States
ETF Hub
Find the right ETFs for your portfolio: Visit Seeking Alpha's ETF Hub